Skip to main content

Advertisement

Table 1 Indirect treatment comparison between TBZ and DEU (as reported by us in Rodrigues et al. [5]), both in odds ratios as initially reported, and converted to risk differences; and as reported by Claassen et al. [1] as risk differences

From: Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease”

Adverse event Indirect comparison
Rodrigues et al. [5] Claassen et al. [1]
OR (95% CI)
(TBZ vs DEU)
RD (95% CI)
(DEU vs TBZ)
RD (95% CI)
(DEU vs TBZ)
SAE 5.44 (0.09 to 322.08) −0.07 (−0.17 to 0.03) −0.074 (−0.167 to 0.019)
Somnolence 4.95 (0.34 to 72.37) −0.21 (−0.39 to −0.03)* −0.215 (−0.392 to −0.037)*
Diarrhoea 0.07 (0.03 to 2.06) 0.12 (−0.03 to 0.27) 0.115 (−0.038 to 0.268)
Insomnia 14.18 (0.47 to 426.77) −0.24 (−0.40 to −0.04)* −0.237 (−0.387 to −0.087)*
Fatigue 1.21 (0.31 to 11.14) −0.07 (−0.26 to 0.12) −0.067 (−0.256 to 0.123)
Falls 2.71 (0.31 to 23.98) −0.07 (−0.26 to 0.12) −0.078 (−0.265 to 0.110)
Depression 17.15 (0.55 to 531.90) −0.17 (−0.31 to −0.28)* −0.170 (−0.304 to −0.037)*
  1. Presentation as risk differences produces statistically significant differences between DEU and TBZ that are not seen when presented as odds ratios; neither approach is intrinsically more accurate and an awareness of the difference is important. TBZ, tetrabenazine; DEU, deutetrabenazine; OR, odds ratio; 95% CI, 95% confidence interval; RD, risk difference; SAE, severe adverse events; *p-value < 0.05